An experimental RNA medicine has produced one of the clearer target-engagement signals yet reported in Huntington disease. That is important, but it is not the same as slowing the illness.
Alnylam announced on 23 October 2026 that a single dose of brezosiran, previously called ALN-HTT02, produced dose-dependent reductions in mutant huntingtin protein in cerebrospinal fluid. In the highest dose group evaluated so far, the mean reduction at month three was 60% to 64%, with one participant reaching 83%.
Silencing the message before the protein is made
Huntington disease is caused by an expanded CAG repeat in the HTT gene. The altered gene produces forms of huntingtin protein that damage neurons over time, leading to movement, cognitive and psychiatric symptoms.
Brezosiran uses RNA interference, or RNAi. A small interfering RNA molecule is designed to recognise huntingtin messenger RNA—the temporary genetic instruction used to make the protein—and direct the cell to destroy that message. The drug targets exon 1, so it is intended to reduce both full-length huntingtin and a shorter form called HTT1a.
The treatment is delivered intrathecally, meaning into the fluid surrounding the spinal cord. Alnylam’s C16 chemical conjugate is designed to help the RNA molecule enter cells in the central nervous system.
What the Phase 1b trial can establish
The ongoing Phase 1b study, NCT06585449, is randomised, double-blind and placebo-controlled. It enrolled 48 adults aged 25 to 70 across five single-ascending-dose cohorts; a sixth cohort is still enrolling. Participants have genetically confirmed disease at Huntington’s Disease Integrated Staging System stage 2 or early stage 3.
Its main jobs are to assess safety, tolerability, how the drug moves through the body, and whether it reaches its biological target. Two independent assays detected mutant-huntingtin lowering. Follow-up in some participants extends to 12 months, and the pattern so far suggests that dosing every six months might be possible.
The company also reported no dose-dependent increase in cerebrospinal-fluid inflammatory markers, neurofilament light chain or brain ventricular volume. That is an encouraging early safety observation, not proof of long-term safety. Rare adverse effects and consequences of sustained huntingtin reduction may only emerge in larger studies.
A biomarker win still needs a clinical test
The central uncertainty is whether lowering huntingtin in spinal fluid preserves neurons or changes how people feel and function. This small dose study was not designed to answer that question, and it has not reported evidence that brezosiran slows movement, cognitive or behavioural decline.
Huntingtin also has normal biological roles, while brezosiran is designed to lower both mutant and non-mutant forms. The balance between sufficient suppression and long-term tolerability therefore matters.
Delivery is part of the experiment
RNA medicines work only if they reach the relevant cells and remain active for a useful period. An intrathecal injection bypasses the blood–brain barrier, but drug distribution can still differ across regions of the brain and spinal cord. A spinal-fluid biomarker is accessible and informative, yet it is an indirect window into target engagement inside vulnerable neurons.
That is why the durability signal is operationally important. Twice-yearly treatment would be less burdensome than frequent spinal injections, but the proposed interval must be confirmed with repeated dosing. The open-label extension should help reveal whether suppression is consistent, reversible and tolerable over several years.
Eligible participants can enter an open-label extension with dosing every six months for up to 36 months. Alnylam says it plans a placebo-controlled pivotal study in 2027, subject to regulatory alignment. Until such a trial reports clinical outcomes, brezosiran should be understood as an investigational RNAi therapy with strong early target engagement—not a demonstrated disease-modifying treatment.
Leave a Reply